Skip to main content


Privacy & Security
The Substance Abuse and Mental Health Services Administration has proposed a series of revisions to 42 CFR Part 2 regulations to facilitate better care coordination for the treatment of substance use disorders.
Legislators’ overly narrow focus on opioids, Google’s overpowering presence in online marketing, and telehealth best practices were among the topics covered Thursday at NCAD East.
An executive order by President Donald Trump announced on Monday could bring greater transparency to healthcare costs, but information needs to be “understandable and actionable” observers say.
Business Strategy
The time for polite debate and noble legislation has passed. Behavioral healthcare needs collective action driven by leaders and politicians who live up to their words.
Kentucky served as a somewhat unlikely model in a National Governors Association initiative to stimulate innovative responses to the infectious disease effects of the opioid crisis. 
Rep. Katherine Clark (D-MA) and Rep. Hal Rogers (R-KY) have accused the World Health Organization of allowing Purdue Pharma to have undue influence in the creation of its opioid prescribing guidelines, citing multiple WHO documents that repeat the…
Ron Manderscheid
A Congressional briefing held earlier this week addressed the decarceration of transition age youth with intellectual/developmental disabilities (I/DD) and mental disorders, with presentations outlining the issue, its impact, including upon families…
In his new book, attorney Harry Nelson, founder of the Nelson Hardiman healthcare law firm, says the opioid epidemic is a structural challenge that requires more than late-stage interventions and policymaking.
Changes to medical marijuana laws, use of PDMPs state-by-state, and access to naloxone were among the legal topics covered during a breakout session Thursday at the Rx Summit.
President Donald Trump pledged his administration’s support for providers and officials in the opioid crisis fight and highlighted various initiatives during an address at the Rx Drug Abuse & Heroin Summit.
Ed Thompson, president of Pharmaceutical Manufacturing Research Services, explained to attendees at the Rx Drug Abuse & Heroin Summit why he wants the FDA to start requiring substantial scientific evidence of efficacy for the intended use of new…
Back to Top